-+ 0.00%
-+ 0.00%
-+ 0.00%

Is Mineralys Therapeutics (MLYS) Cheap As Transform HTN Data Strengthens Its FDA Case?

Simply Wall St·11/16/2026 04:31:21
Listen to the news

Mineralys Therapeutics (MLYS) drew fresh attention after releasing long term Transform-HTN extension data for lorundrostat, which showed sustained systolic blood pressure reductions over 48 weeks alongside a reported favorable safety and tolerability profile.

The new Transform-HTN data lands after a tough run for Mineralys Therapeutics shareholders, with the stock down 24.48% on a 30 day share price return and 57.07% on a year to date share price return, even though the 3 year total shareholder return is up 138.41%.

Spot 19 high quality undiscovered gems that, like Mineralys Therapeutics after its Transform-HTN readout, could be quietly building clinical momentum before sentiment catches up.

Mineralys Therapeutics now trades at a steep discount to both analyst targets and intrinsic value estimates after the latest Transform-HTN data. Is that a pricing error, or a clear signal that market caution on this loss-making biotech is warranted?

Most Popular Narrative: 66% Undervalued

On the analyst consensus Narrative on Simply Wall St, Mineralys Therapeutics screens as materially undervalued, with a fair value of about $45.22 against a last close of $15.33. This comparison puts the recent Transform-HTN data into a very different pricing context.

Progress toward an NDA filing for lorundrostat in uncontrolled and resistant hypertension, supported by multiple Phase III and proof of concept trials, positions the company to potentially transition from a pure R&D story toward a revenue generating profile, which could materially affect future revenue and earnings visibility.

See why 4 investors see Mineralys Therapeutics as 66% undervalued.

Result: Fair Value of $45.22 (UNDERVALUED)

Still, the narrative around Mineralys Therapeutics hinges on regulatory approval for lorundrostat and on overcoming class competition that could slow real world adoption.

Find out about the key risks to this Mineralys Therapeutics narrative.

Another View: Multiples Paint A Pricier Picture For Mineralys Therapeutics

The story looks very different when you swap future cash flows for a simple market ratio. Mineralys Therapeutics trades on a P/B of 2.7x, compared with 1.8x for the wider US Biotechs group and 18.9x for closer peers. That gap suggests the stock could already carry a premium on balance sheet value, even while DCF fans see upside. Which lens do you trust more when real revenue is still ahead of it?

For a closer look at how this valuation approach stacks up against peers and what that might mean for risk, see See what the numbers say about this price — find out in our valuation breakdown..

NasdaqGS:MLYS P/B Ratio as at Nov 2026
NasdaqGS:MLYS P/B Ratio as at Nov 2026

Next Steps

Mixed signals around Mineralys Therapeutics can be confusing, so consider reviewing the data for yourself and weighing both sides through 2 key rewards and 2 important warning signs.

Looking For More Investment Ideas Beyond Mineralys Therapeutics?

If you only focus on Mineralys Therapeutics, you could miss other shares that fit your style even better. Broaden your watchlist with focused screeners instead.